The present invention generally relates to homeopathic compositions, and, more particularly, (i) homeopathic compositions comprising a homeopathically potentised form of Passiflora incarnata (Passionflower), and a homeopathically potentised form of Nux Moschata (Nutmeg); or (ii) a homeopathically potentised Carbo Vegetabilis; and a homeopathically potentised Passiflora incarnata; or (iii) a homeopathically potentised Carbo Vegetabilis; and a homeopathically potentised Nux Moschata; and methods of treatment using these homeopathic compositions.

The present invention generally relates to homeopathic compositions, and, more particularly, (i) homeopathic compositions comprising a homeopathically potentised form of Passiflora incarnata (Passionflower), and a homeopathically potentised form of Nux Moschata (Nutmeg); or (ii) a homeopathically potentised Carbo Vegetabilis; and a homeopathically potentised Passiflora incarnata; or (iii) a homeopathically potentised Carbo Vegetabilis; and a homeopathically potentised Nux Moschata; and methods of treatment using these homeopathic compositions.

Disclosed are a pharmaceutical composition, cosmetic product, and food or drink product each comprising a porous ceramic obtained by combustion synthesis of a starting material comprising (1) titanium and (2) at least one member selected from the group consisting of carbon, boron, nitrogen, and silicon; a pharmaceutical composition and cosmetic product each comprising a radical- and nanobubble-containing liquid; and a blood treatment device comprising a blood flow channel for extracorporeal circulation of a patient's blood, the blood flow channel being provided with the porous ceramic above, and the porous ceramic and the blood are brought into contact with each other.

Disclosed are a pharmaceutical composition, cosmetic product, and food or drink product each comprising a porous ceramic obtained by combustion synthesis of a starting material comprising (1) titanium and (2) at least one member selected from the group consisting of carbon, boron, nitrogen, and silicon; a pharmaceutical composition and cosmetic product each comprising a radical- and nanobubble-containing liquid; and a blood treatment device comprising a blood flow channel for extracorporeal circulation of a patient's blood, the blood flow channel being provided with the porous ceramic above, and the porous ceramic and the blood are brought into contact with each other.

The present invention relates to hyper harmonized hydroxyl-modified fullerenes, hydroxyl-modified fullerenes in a suitable carrier, and hydroxyl-modified fullerene formulations including a suitable carrier with optional additives. These compositions of matter and formulations have numerous applications including, for example, the cosmetic industry, dietary supplements, food industry, plants and healthcare fields.

The present invention relates to hyper harmonized hydroxyl-modified fullerenes, hydroxyl-modified fullerenes in a suitable carrier, and hydroxyl-modified fullerene formulations including a suitable carrier with optional additives. These compositions of matter and formulations have numerous applications including, for example, the cosmetic industry, dietary supplements, food industry, plants and healthcare fields.

The present invention relates to a pharmaceutical composition which contains activated charcoal, Carum carvi extract, papain and, optionally, α-galactosidase and β-galactosidase for the treatment of gastrointestinal disorders.

The present invention relates to a pharmaceutical composition which contains activated charcoal, Carum carvi extract, papain and, optionally, α-galactosidase and β-galactosidase for the treatment of gastrointestinal disorders.

The present invention relates to a pharmaceutical composition for preventing or treating chronic kidney disease, the composition including graphene quantum dots as an active ingredient. Graphene quantum dots according to the present invention were observed to exhibit the effects of decreasing the expression of fibronectin, collagen 1al, Bax, TGF-β1, Smad2/3, α-SMA, etc., which are renal fibrosis-related proteins, and increasing the expression of E-cadherin, Smad7, MnSOD, and SOD1, and thereby suppress renal fibrosis. Accordingly, it is expected that the graphene quantum dots according to the present invention will be able to be effectively used in the field of developing agents for treating or alleviating chronic kidney disease caused by renal fibrosis.

The present invention relates to a pharmaceutical composition for preventing or treating chronic kidney disease, the composition including graphene quantum dots as an active ingredient. Graphene quantum dots according to the present invention were observed to exhibit the effects of decreasing the expression of fibronectin, collagen 1al, Bax, TGF-β1, Smad2/3, α-SMA, etc., which are renal fibrosis-related proteins, and increasing the expression of E-cadherin, Smad7, MnSOD, and SOD1, and thereby suppress renal fibrosis. Accordingly, it is expected that the graphene quantum dots according to the present invention will be able to be effectively used in the field of developing agents for treating or alleviating chronic kidney disease caused by renal fibrosis.